Trial Profile
Evaluate the Safety and Efficacy of Chimeric Antigen Receptor Engineered T Cell Immunotherapy (CAR-T) in the Treatment of Pancreatic Cancer in a Single Center, Non Controlled Clinical Study.
Status:
Recruiting
Phase of Trial:
Phase 0
Latest Information Update: 05 Aug 2019
Price :
$35
*
At a glance
- Drugs Anti-CD19 chimeric antigen receptor T cell therapy Shanghai Unicar Therapy Bio-medicine Technology (Primary)
- Indications Pancreatic cancer
- Focus Therapeutic Use
- 01 Sep 2017 New trial record